Henry Schein to sell hematology systems

Medical products distributor Henry Schein (HSIC) inks a 3-year distribution deal with Sysmex to sell its line of hematology analyzers in the alternate care setting.

Consensus estimates for Q1 and 2014 are EPS of $1.13 on revenues of $2.43B and EPS of $5.37 on revenues of $10.2B, respectively.

780 mutual funds have positions in the stock.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs